Cargando…
A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease
The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to v...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836410/ https://www.ncbi.nlm.nih.gov/pubmed/35163772 http://dx.doi.org/10.3390/ijms23031850 |
_version_ | 1784649672044838912 |
---|---|
author | Zimmermann, Julie Schmidt, Signe Tandrup Trebbien, Ramona Cox, Rebecca Jane Zhou, Fan Follmann, Frank Pedersen, Gabriel Kristian Christensen, Dennis |
author_facet | Zimmermann, Julie Schmidt, Signe Tandrup Trebbien, Ramona Cox, Rebecca Jane Zhou, Fan Follmann, Frank Pedersen, Gabriel Kristian Christensen, Dennis |
author_sort | Zimmermann, Julie |
collection | PubMed |
description | The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to vaccine approval. The liposomal vaccine adjuvant CAF(®)09b contains the TLR3 agonist polyinosinic:polycytidylic acid, which induces a type I interferon (IFN-I) response and an antiviral state in the affected tissues. When testing CAF09b liposomes as a potential pan-viral prophylaxis, we observed that intranasal administration of CAF09b liposomes to mice resulted in an influx of innate immune cells into the nose and lungs and upregulation of IFN-I-related gene expression. When CAF09b liposomes were administered prior to challenge with mouse-adapted influenza A/Puerto Rico/8/1934 virus, it protected from severe disease, although the virus was still detectable in the lungs. However, when CAF09b liposomes were administered after influenza challenge, the mice had a similar disease course to controls. In conclusion, CAF09b may be a suitable candidate as a pan-viral prophylactic treatment for epidemic viruses, but must be administered prior to virus exposure to be effective. |
format | Online Article Text |
id | pubmed-8836410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88364102022-02-12 A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease Zimmermann, Julie Schmidt, Signe Tandrup Trebbien, Ramona Cox, Rebecca Jane Zhou, Fan Follmann, Frank Pedersen, Gabriel Kristian Christensen, Dennis Int J Mol Sci Article The SARS-CoV-2 pandemic caused a massive health and societal crisis, although the fast development of effective vaccines reduced some of the impact. To prepare for future respiratory virus pandemics, a pan-viral prophylaxis could be used to control the initial virus outbreak in the period prior to vaccine approval. The liposomal vaccine adjuvant CAF(®)09b contains the TLR3 agonist polyinosinic:polycytidylic acid, which induces a type I interferon (IFN-I) response and an antiviral state in the affected tissues. When testing CAF09b liposomes as a potential pan-viral prophylaxis, we observed that intranasal administration of CAF09b liposomes to mice resulted in an influx of innate immune cells into the nose and lungs and upregulation of IFN-I-related gene expression. When CAF09b liposomes were administered prior to challenge with mouse-adapted influenza A/Puerto Rico/8/1934 virus, it protected from severe disease, although the virus was still detectable in the lungs. However, when CAF09b liposomes were administered after influenza challenge, the mice had a similar disease course to controls. In conclusion, CAF09b may be a suitable candidate as a pan-viral prophylactic treatment for epidemic viruses, but must be administered prior to virus exposure to be effective. MDPI 2022-02-06 /pmc/articles/PMC8836410/ /pubmed/35163772 http://dx.doi.org/10.3390/ijms23031850 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zimmermann, Julie Schmidt, Signe Tandrup Trebbien, Ramona Cox, Rebecca Jane Zhou, Fan Follmann, Frank Pedersen, Gabriel Kristian Christensen, Dennis A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease |
title | A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease |
title_full | A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease |
title_fullStr | A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease |
title_full_unstemmed | A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease |
title_short | A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease |
title_sort | novel prophylaxis strategy using liposomal vaccine adjuvant caf09b protects against influenza virus disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836410/ https://www.ncbi.nlm.nih.gov/pubmed/35163772 http://dx.doi.org/10.3390/ijms23031850 |
work_keys_str_mv | AT zimmermannjulie anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT schmidtsignetandrup anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT trebbienramona anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT coxrebeccajane anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT zhoufan anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT follmannfrank anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT pedersengabrielkristian anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT christensendennis anovelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT zimmermannjulie novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT schmidtsignetandrup novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT trebbienramona novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT coxrebeccajane novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT zhoufan novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT follmannfrank novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT pedersengabrielkristian novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease AT christensendennis novelprophylaxisstrategyusingliposomalvaccineadjuvantcaf09bprotectsagainstinfluenzavirusdisease |